Description

TRESIBA FLEXTOUCH 100 UNITS

Indications

TRESIBA FLEXTOUCH 100 UNITS is indicated for the management of diabetes mellitus in adults and children aged 1 year and older. It is used to improve glycemic control in patients with type 1 and type 2 diabetes. TRESIBA can be administered alone or in combination with other antidiabetic agents, including oral medications and insulin.

Mechanism of Action

TRESIBA FLEXTOUCH contains insulin degludec, a long-acting insulin analog. Its mechanism of action involves the regulation of glucose metabolism. Insulin degludec forms multi-hexamers upon subcutaneous injection, leading to a slow and steady release into the bloodstream. This results in a prolonged duration of action, allowing for once-daily dosing to maintain stable blood glucose levels throughout the day and night.

Pharmacological Properties

The pharmacokinetics of TRESIBA FLEXTOUCH demonstrate a peakless profile, which minimizes the risk of hypoglycemia associated with traditional insulins. The onset of action occurs within 30 to 90 minutes after injection, with a duration of action lasting up to 42 hours. This extended action allows for flexibility in dosing times, making it suitable for patients with varying lifestyles and schedules.

Contraindications

TRESIBA FLEXTOUCH is contraindicated in patients with hypersensitivity to insulin degludec or any of the excipients in the formulation. It is also not recommended for individuals experiencing episodes of hypoglycemia or those with conditions that may predispose them to severe hypoglycemia.

Side Effects

Common side effects associated with TRESIBA FLEXTOUCH include hypoglycemia, injection site reactions (such as redness, swelling, or itching), and weight gain. Other potential side effects may include allergic reactions, lipodystrophy, and in rare cases, severe hypersensitivity reactions. Patients should be monitored for signs of hypoglycemia, particularly when initiating therapy or adjusting doses.

Dosage and Administration

TRESIBA FLEXTOUCH is administered subcutaneously, typically once daily at any time of the day, but at the same time each day for optimal results. The initial dose of TRESIBA should be individualized based on the patient’s needs, previous insulin therapy, and blood glucose monitoring results. Dosage adjustments may be necessary based on factors such as changes in diet, physical activity, or concurrent medications. It is important to rotate injection sites to minimize the risk of lipodystrophy.

Interactions

Drug interactions may occur with TRESIBA FLEXTOUCH. Certain medications, such as corticosteroids, thiazide diuretics, and sympathomimetics, may increase blood glucose levels and necessitate adjustments in insulin dosage. Conversely, other medications, such as sulfonylureas and meglitinides, may potentiate the effects of insulin, increasing the risk of hypoglycemia. Patients should inform their healthcare provider of all medications they are taking to ensure safe and effective use of TRESIBA.

Precautions

Patients using TRESIBA FLEXTOUCH should be educated on the signs and symptoms of hypoglycemia and the importance of regular blood glucose monitoring. Caution is advised when using TRESIBA in patients with renal or hepatic impairment, as these conditions may affect insulin metabolism and clearance. Additionally, patients should be advised to carry a source of glucose at all times to treat potential hypoglycemic episodes.

Clinical Studies

Clinical studies have demonstrated the efficacy and safety of TRESIBA FLEXTOUCH in managing blood glucose levels in both type 1 and type 2 diabetes. In a pivotal trial comparing TRESIBA to insulin glargine, TRESIBA was shown to provide similar glycemic control with a lower incidence of nocturnal hypoglycemia. Long-term studies have also indicated that TRESIBA helps maintain weight stability compared to other insulin therapies, making it a favorable option for many patients.

Conclusion

TRESIBA FLEXTOUCH 100 UNITS is a valuable therapeutic option for individuals managing diabetes mellitus. Its unique pharmacological properties, including a peakless action profile and extended duration, allow for flexible dosing and improved glycemic control. As with any insulin therapy, careful monitoring and patient education are essential to optimize treatment outcomes and minimize risks.